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Abstract
Background: The normal human prostate glandular epithelium has the unique function of accumulating
high levels of zinc. In prostate cancer this capability is lost as an early event in the development of the
malignant cells. The mechanism and factors responsible for the ability of the normal epithelial cells to
accumulate zinc and the loss of this capability in the malignant cells need to be identified. We previously
reported that Zip1 is an important zinc uptake transporter in prostate cells and is down regulated in the
malignant cells in situ along with the depletion of zinc levels. In this report we investigated the expression
of two other Zip family zinc transporters, Zip2 and Zip3 in malignant versus nonmalignant (normal and
BPH) glands. Zip2 and Zip3 relative protein levels were determined by immunohistochemistry analysis of
human prostate tissue sections.
Results: Normal and BPH glandular epithelium consistently exhibited the strong presence of both Zip 2
and Zip3; whereas both transporters consistently were essentially non-detectable in the malignant glands.
This represents the first report of the expression of Zip3 in human prostate tissue; and more importantly,
reveals that ZiP2 and Zip3 are down regulated in malignant cells in situ as we also had demonstrated for
Zip1. Zip2 and Zip3 transporter proteins were localized predominantly at the apical cell membrane, which
is in contrast to the Zip1 localization at the basolateral membrane. Zip2 and Zip3 seemingly are associated
with the re-uptake of zinc from prostatic fluid.
Conclusion: These results coupled with previous reports implicate Zip2 and Zip3 along with Zip1 as
important zinc uptake transporters involved in the unique ability of prostate cells to accumulate high
cellular zinc levels. Zip1 is important for the extraction of zinc from circulation as the primary source of
cellular zinc. Zip 2 and Zip3 appear to be important for retention of the zinc in the cellular compartment.
The down regulation of all three transporters in the malignant cells is consistent with the loss of zinc
accumulation in these cells. Since zinc imposes tumor suppressor effects, the silencing of the gene
expression for these transporters is a required event for the manifestation of the malignant activities of
the neoplastic cells. This now provides new insights into the genetic/molecular events associated with the
development of prostate cancer; and supports our concept of Zip1, and now Zip2 and Zip3, as tumor
suppressor genes and zinc as a tumor suppressor agent.
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Background
It has long been established that the normal human pros-
tate gland has the major function and capability of accu-
mulating uniquely high levels of zinc; generally about ten-
fold greater than other soft tissues. This capability resides
within the glandular secretory epithelial cells of the
peripheral zone, which is the major site of origin of most
prostate malignancy. Over fifty years of clinical studies
have consistently demonstrated that prostate cancer tissue
samples consistently contain about 65% less zinc than
normal prostate tissue. More precisely, the zinc concentra-
tion (nmols/gram wet weight) of normal peripheral zone
tissue approximates 3,000–4,500; malignant peripheral
zone tissue approximates 400–800; and other soft tissues
approximate 200–400. Consequently, malignant prostate
tissue zinc levels are decreased by ~70–85% compared to
normal peripheral zone; and the decrease is observed in
the glandular epithelial cells. Most importantly, one
rarely, if ever, finds malignant glands that have retained
the high zinc levels that characterize the normal gland. In
addition, the decrease in zinc occurs early in the develop-
ment of prostate malignancy. These established clinical
relationships have raised important issues that relate to
the role and mechanisms of zinc accumulation in the nor-
mal functioning of the prostate gland, and the loss of zinc
accumulation as a requirement in the development of
prostate malignancy. For expanded background discus-
sion and review of these relationships see our recent
papers [1-3].
The accumulation of zinc results in several important
effects on prostate cells. The functional role of zinc accu-
mulation is to inhibit citrate oxidation of the highly spe-
cialized secretory epithelial cells, which permits the
production and secretion of extremely high levels of cit-
rate as a major component of prostatic fluid. In addition
to its functional role, the accumulation of zinc has conse-
quential effects that include: metabolic effects such as
inhibition of terminal oxidation, truncation of the Krebs
cycle, decreased energy production; growth/proliferation
inhibition effects such as induction of mitochondrial
apoptogenesis; and inhibition of invasiveness and motil-
ity. The combination of such effects can be characterized
as anti-tumor effects, which lead us to propose that zinc is
a tumor-suppressor agent against prostate cancer. This
provides the explanation for the requirement that malig-
nant cells lose the capability to accumulate zinc and the
basis for the absence of malignant glands that retain high
levels of zinc.
This has led us to pursue the critical issues regarding the
mechanism of zinc accumulation in the normal epithelial
cells and the mechanism of the lost ability of the malig-
nant cells to accumulate zinc. The members of the Zip
family of zinc transporters have been identified as impor-
tant zinc transporters for the cellular uptake and accumu-
lation of zinc in mammalian cells. More specifically, we
have identified Zip1 as an important zinc uptake trans-
porter in prostate cells [4,5]. Our recent report [6] demon-
strated that Zip1 is expressed in human normal and
hyperplastic prostate glandular epithelium; and is down-
regulated in adenocarcinomatous glands. Correspond-
ingly, the high cellular zinc level is markedly depleted in
the malignant glands. In addition Rishii et al [7] identified
the down regulation of Zip1 expression in the high pros-
tate cancer at-risk African American male population as
compared with Caucasians. These relationships cause us
to propose that Zip1 is a candidate tumor suppressor gene
in prostate cancer. However, the expression and role of
other Zip-family transporters in prostate malignancy have
not been established. In this report we identify by immu-
nohistochemistry the expression of Zip2 and Zip3 in non-
malignant prostate tissue sections and their down-regula-
tion in malignant prostate glands. The potential relevance
of these zinc transporters in normal and malignant pros-
tate is described.
Results
Figures 1 and 2 show representative results of the Zip2
and Zip3 immunohistochemical staining observed in nor-
mal, BPH glands, and adenocarcinomatous glands,
respectively. The glandular epithelium of the normal and
BPH glands exhibits immuno-positive Zip2 and Zip3,
both of which exhibit staining that is localized predomi-
nantly at the apical cell membrane of the secretory epithe-
lium. In contrast, in the adenocarcinomatous glands both
transporters are negligible to absent in the malignant cell
Immunohistochemical detection of Zip2 transporter protein  in normal, BPH and malignant sections of representative  prostate tissues Figure 1
Immunohistochemical detection of Zip2 transporter protein 
in normal, BPH and malignant sections of representative 
prostate tissues. Note the immuno-positivity of the apical 
plasma membrane of normal and BPH glands (black arrows). 
The malignant glands show no detectable Zip2 membrane 
immunoreactivety (red arrows).Molecular Cancer 2007, 6:37 http://www.molecular-cancer.com/content/6/1/37
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membranes. It is also evident that both Zip transporter
proteins studied are minimally detected in the stromal tis-
sue.
Tables 1 and 2 provide the summary of the comparative
immunohistochemical scoring of hZip2 and Zip3 reactiv-
ity of normal, BPH, and malignant prostate glands respec-
tively. Normal glands and BPH glands are both zinc-
accumulating glands as contrasted with malignant glands
that do not accumulate high zinc levels. Only 4 of 30 com-
bined normal plus BPH cases were negative for Zip2, com-
pared to 21 of 24 malignant cases being negative. None of
the 30 normal plus BPH cases was negative Zip3, com-
pared to 21 of 24 malignant cases being negative. The
results clearly establish that both Zip2 and Zip3 are down
regulated in malignant prostate glands
The down regulation of Zip2 and Zip3 is nearly identical
to the down regulation of Zip1 that we had previously
reported [6]. Table 3 shows the composite results from
this study and our previous study of Zip1 for the three
transporters in identical subjects. Of the twenty-one com-
mon tissue samples from subjects, thirteen showed nega-
tivity of all three transporters, and seven cases showed
either negative or low immunopositivity (+) for all three
transporters in the malignant glands. Therefore, twenty of
the twenty-one cases showed negative or lowest level of
immuno-positivity for all three transporters. This reveals
the consistency of down regulation of Zip transporters in
malignant glands. In addition, we earlier reported that m-
aconitase IHC performed with the same samples repre-
sented in Table 3 showed no difference between the
malignant and BPH glands [8]. This reveals the specificity
of the down regulation of the Zip transporters. Also as
shown in Table 3, there exists no correlation between the
PCA scoring and the grade of cancer for any of the trans-
porters. This is consistent with our contention that the
zinc and citrate metabolic changes occur in the early stage
of the development of malignancy (perhaps premalignant
stage) and persists through the progression of malig-
nancy; and this would also apply to the down regulation
of the Zip transporters [1-3,6].
However the results also reveal an important difference
between Zip 2 and Zip3 compared to Zip1. Figures 1 and
2 show that Zip2 and Zip3 transporters are localized
nearly exclusively at the apical membrane. This is in con-
Table 1: Zip2 immunopositivity of glandular components in 
prostate tissue sections.
Case noa.Z i p 2  I H C  S C O R E b
Normal BPH Malignant
1 +++ +++ -
2N / A + + -
3N / A + + -
4N / A + + -
5N / A + + -
6 +++ +++ -
7+ + + + + +
8N / A + + + +
9+ + + -
11 N/A ++ -
12 N/A + -
13 N/A ++ -
14 N/A + -
15 N/A + -
16 N/A - -
17 N/A - -
18 N/A +++ -
20 N/A - -
21 N/A ++ -
22 N/A +++ -
23 N/A - -
24 N/A +++ N/A
25 ++ ++ -
26 N/A ++ -
27 N/A +++ +
Neg Zip2 IHC 0/5 4/25 21/24*
Scores > + 5/5 17/25 1/24*
Mean scorec 2.60 1.76 0.17*
aCase number: Cases 1–23 are the same cases from our previous 
studies [6,8]. Cases from 24–27 are new cases.
bScoring of immunoreactivity was done as follows: negative, no 
positive cells; score +, < 10% positive cells; score ++, 10–50% positive 
cells; score +++, > 50% positive cells.
cMean score: Mean for each group was obtained by the sum of the 
+'s/number of cases.
*P < 0.001 for malignant vs normal or vs BPH.
Immunohistochemical detection of Zip3 transporter protein  in normal, BPH and malignant sections of representative  prostate tissues Figure 2
Immunohistochemical detection of Zip3 transporter protein 
in normal, BPH and malignant sections of representative 
prostate tissues. (top; magnifications are ×400). Note the 
immuno-positivity of the apical plasma membrane of normal 
and BPH glands (black arrow). The malignant glands show no 
detectable Zip3 membrane immunoreactivety (red arrows).Molecular Cancer 2007, 6:37 http://www.molecular-cancer.com/content/6/1/37
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trast to our earlier report that showed the dominant local-
ization of Zip1 at the basolateral membrane. This is
further revealed in figure 3, which shows the definitive
Zip1 immunostaining of the basolateral membrane and
the apical membrane of the normal prostate glandular
epithelial cells. Note also the absence of Zip1 in the
stroma. The limitation of Zip2 and Zip3 to the apical sur-
face raises important issues concerning the functional role
of these transporters (discussed below).
Discussion
This report coupled with our earlier study reveals that
Zip1, Zip2, and Zip3 are expressed in situ in normal pros-
tate glandular epithelial cells and also in hyperplastic
glandular epithelium; both of which are zinc-accumulat-
ing glands. This is the first report that identifies the expres-
sion of Zip3 in human prostate glands. In contrast, the
expression of all three transporters is consistently down-
regulated in adenocarcinomatous glands, which are
known to have lost the ability to accumulate zinc. These
results coincide with the numerous reports that have
established the consistently marked decrease in the zinc
levels of prostate cancerous tissue as compared to normal
and BPH prostate tissue. Thus, the expression of these Zip
family zinc uptake transporters in normal and BPH glands
and the loss of their expression in malignant glands are
further evidence of their role in the cellular accumulation
of zinc, or lack thereof, in prostate cells. It is notable that
Rishii et al [7] reported the down regulation of expression
of Zip 2 as well as Zip1 in African-American males.
The localization of Zip1 at the basolateral membrane of
normal glandular epithelial cells is consistent with its cel-
lular function to transport zinc from the interstitial fluid
derived from blood plasma into the cell. Therefore, Zip1
provides the source of the cellular zinc. Correspondingly,
the down regulation of Zip1 in malignant cells is consist-
ent with their inability to accumulate zinc. However the
present study shows that Zip2 and Zip3, unlike Zip1,
exhibit little or no localization at the basolateral mem-
brane, and are confined predominantly to the apical
membrane. Studies with cell lines have shown that Zip2
and Zip3 function as zinc uptake transporters [9,10].
Therefore the in situ apical membrane localization indi-
cates that Zip 2 and Zip3, unlike Zip1, do not function to
accumulate cellular zinc from circulation. If one presumes
that they retain zinc uptake transporter activity in situ,
their functional role might be to conserve the cellular zinc
level by transporting (reabsorbing) zinc from the prostatic
fluid back into the epithelial cell. Normal prostatic fluid
has a high zinc concentration of ~9 mM compared to
interstitial fluid zinc level of ~7 uM. At this high prostatic
fluid concentration and depending upon the Km value of
each transporter for zinc, Zip2 and Zip3 might effectively
contribute to maintaining a high intracellular level of
zinc. This implies that the down-regulation of Zip2 and
Zip3 in the malignant cells would contribute to their loss
of cellular zinc by the elimination of the "reabsorption" of
zinc from prostatic fluid. However, it is Zip1 that is the
major factor since its down regulation eliminates the prin-
cipal source of cellular zinc; namely zinc uptake from cir-
culation. Presently we can only speculate regarding the
role of Zip 2 and Zip3 in zinc accumulation by normal
prostate glands in situ; and the possible implications of
their down regulation in the malignant glands. It is also
notable that Rishii et al [7] had reported that Zip1 and
Zip2 mRNA analysis revealed their expression in normal
prostate glands of Caucasians, but their expression was
down regulated in Black Americans; which appeared to
correlate with the higher incidence of prostate cancer
among this population.
An important issue is the mechanism that is responsible
for the down regulation of the Zip transporters. Because
Zip1 expression reappears in several immortalized pros-
tate cancer cell lines under standard culture conditions,
we have proposed that its down regulation in situ results
Table 2: Zip3 immunopositivity of glandular components in 
prostate tissue sections
Case noa. Zip3 IHC SCOREb
Normal BPH PCa
1+ + -
2N / A + -
3N / A + + + -
4N / A + -
5N / A + + +
6+ + + + -
7+ + + -
8N / A + + +
9+ + + + -
11 N/A +++ -
12 N/A ++ -
13 N/A ++ -
14 N/A + +
15 N/A + -
16 N/A + -
17 N/A ++ -
18 N/A +++ -
20 N/A +++ -
21 N/A ++ -
22 N/A +++ -
23 N/A + -
24 N/A +++ N/A
25 +++ +++ -
26 N/A ++ -
27 N/A +++ -
Neg Zip3 IHC 0/5 0/25 21/24*
Scores > + 4/5 17/25 0/24*
Mean scorec 2.00 2.00 0.13*
See Table 1 for footnotesMolecular Cancer 2007, 6:37 http://www.molecular-cancer.com/content/6/1/37
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from the epigenetic silencing of gene expression [1-3,6].
Similarly, both Zip2 and Zip3 are down regulated in the
primary site malignant glands in situ, but their expression
re-appears in the immortalized prostate cancer cell lines:
Zip3 in RWPE2 cells [9]; Zip2 in PC-3 cells [our unpub-
lished studies]. This leads us to propose that their in situ
down regulation also results from epigenetic effects. Pres-
ently, no information exists regarding the expression of
any of these transporters in metastatic cells in situ. It will
be critically important to establish if the down regulation
in the primary site malignant cells is retained after the
cells intravasate and develop as metastatic cells in distant
tissue sites. This will provide key information regarding
important in situ factors that are involved in the regula-
tion of these important potential tumor-suppressor genes.
We are currently pursuing such studies.
We have proposed that the various effects of zinc in pros-
tate cells constitute tumor-suppressor actions. The func-
tional role of zinc is its prevention of citrate oxidation that
is achieved by its inhibitory actions on m-aconitase activ-
ity [11,12] of the highly specialized citrate-producing
prostate cells. This capability now appears to result from
the expression of the Zip zinc uptake transporters that
maximize the accumulation of cellular zinc. The inhibi-
tion of citrate oxidation and truncation of the Krebs cycle
imposes bioenergetic and metabolic conditions under
which most mammalian cells cannot survive [1-3]. The
high zinc levels also impose other consequential adverse
effects. Zinc induces mitochondrial apoptogenesis and
other effects that inhibit growth and proliferation [1-
Comparative localization of Zip1, Zip2, and Zip3 in prostate  glands Figure 3
Comparative localization of Zip1, Zip2, and Zip3 in prostate 
glands. The black arrows point to the immunopositive stain-
ing at the apical membrane. The blue arrows point to the 
immunopositive staining at the basoloateral membrane.
Table 3: Comparative results for Zip1, Zip2, Zip3, and m-aconitase
Case GRADE^ Zip2 Zip2 Zip3 Zip3 Zip1 Zip1 K^^ ACON ACON
BPH PCA BPH PCA BPH PCA BPH PCA
1 3 +++ - + - +++ - * +++ ++
2 3 ++ - + - ++ + ** + +++
3 1 ++ - +++ - + - * + +
4 2 ++ - + - + - * +++ +++
5 2 ++ - ++ + - - ** ++ +
6 1 +++ - ++ - +++ - * +++ +++
7 2 ++ + + - + + ** ++ +++
8 1 ++ ++ ++ + +++ + +++ ++
9 1 + - ++ - +++ - * + +++
11 2 ++ - +++ - ++ - * + ++
12 1 + - ++ - - - * + +++
13 2 ++ - ++ - ++ - * +++ +++
14 1 + - + + + - ** +++ +++
15 1 + - + - + - * + +
16 1 - - + - + - * ++ +++
17 1 - - ++ - +++ + * ++ -
18 2 +++ - +++ - ++ + ** ++ +++
20 1 - - +++ - + - ** +++ ++
21 1 ++ - ++ - +++ + * +++ +++
22 1 +++ - +++ - - - * +++ +++
23 2 - - + - ND ND ** +++ +++
MEAN SCORE 1.6 0.I4$ 1.85 0.14$ 1.28 0.33$ 2.09 2.38$$
^PCA grading described in reference [6].
^^K = Constant result for PCA scores of Zip1, Zip2, Zip3
* all are negative in PCA;
** all are negative or + in PCA
$ = P < 0.001 PCA vs BPH; $$ = No significant difference PCA vs BPH
Zip1 results taken from reference [6].
Aconitase results taken from reference [8].
ND = not determinedMolecular Cancer 2007, 6:37 http://www.molecular-cancer.com/content/6/1/37
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3,10,13-15]. Obviously, the normal glandular epithelial
cells under in situ conditions have evolved with mecha-
nisms and adaptations that prevent these adverse effects.
Apparently the neoplastic malignant cell is susceptible to
these adverse effects of high cellular zinc. In addition, zinc
also imposes inhibitory effects on mobility and invasive-
ness of malignant prostate cells [16,17]. To avoid these
effects, the neoplastic cell decreases its cellular zinc level
by down regulation of the Zip zinc uptake transporters,
which is why malignant prostate glands virtually always
exhibit low zinc levels in contrast to the high zinc levels
that characterize normal prostate glands. In the absence of
high zinc levels, the synthetic, bioenergetic, growth and
proliferation, and invasive requirements of malignancy
can be manifested. Consequently we propose that zinc is
a tumor-suppressor agent; and Zip1, along with Zip2 and
Zip3, is a tumor suppressor gene in prostate cancer.
Conclusion
Immunohistochemical examination of human prostate
tissue sections reveals the existence of the zinc uptake
transporters hZip2 and hZip3 in the zinc-accumulating
normal and BPH human prostate glandular epithelium.
Most importantly, we also show that both hZip2 and
hZip3 are markedly down regulated in adenocarcinoma-
tous glands, which have lost the ability to accumulate
zinc. These results are similar to earlier observations with
hZip1. Unlike hZip1, hZip2 and hZip3 transporters are
confined to the apical membrane with little or no demon-
strable transporter protein evident at the basolateral
membrane. hZip2 and hZip3 appear to function for the
re-uptake and conservation of zinc from prostatic fluid,
and hZip1 functions for the accumulation of zinc from
circulation. This combination optimizes the cellular accu-
mulation of zinc in normal prostate glands. Since zinc
accumulation exhibits tumor suppressor actions, the
down regulation of these transporters in the malignant
cells is essential for the cellular depletion of zinc to pre-
vent the anti-tumor effects of zinc. These findings are con-
sistent with our concept that Zip1, and now Zip2 and
Zip3, are tumor-suppressor genes in prostate cancer; and
provide the explanation and genetic/molecular/metabolic
mechanism for the virtual absence of malignant prostate
glands that retain the high zinc levels that characterize the
normal glands.
Methods
Human tissue samples
Formalin fixed paraffin embedded prostatic tissue sec-
tions were used in this current study. The studies were
conducted with twenty-five prostatic adenocarcinoma
cases of which twenty-four contained both BPH and ade-
nocarcinomatous foci, and five cases also showed normal
prostatic acini. The cases numbered 1–23 were the same
samples that were used for Zip1 and m-aconitase immu-
nohistochemistry studies presented in our earlier reports
[6,8], and cases numbered 24–27 are new samples. The
immunohistochemical analysis of the prostate tissue sec-
tions were conducted without the identification of the
subjects involved in study.
Immunohistochemistry of human prostatic tissue sections
Immunohistochemistry with anti-hZip2 and anti-hZip3
antibodies was performed as described [6] with modifica-
tion. Briefly, the slides were deparaffinized by heating at
60 degrees for one hour followed by xylene and ascending
grades of alcohol washes. Antigen retrieval was done by
heating in Dako sodium citrate buffer at 98°C. Dako
Autostainer programmed as follows; 30 min with Block-
ing Buster, 1 hour with either 1.2 ug/ml of anti-Zip2 or 0.8
ug/ml of anti-Zip 3 diluted in Dako antibody diluent, fol-
lowed by incubation with anti chicken IgY HRP conjugate
rabbit secondary antibody in a dilution of 1:200
(Promega, cat # G1351) for 30 minutes. Color was devel-
oped by incubating slides with DAB+ Chromogen (Dako,
Code # K4007) followed by Hematoxylin counterstain-
ing. Sections were examined with light BX40 Olympus
Microscope. Pictures were taken with digital camera. The
appearance of membrane-associated immuno-positivity
for Zip2 and Zip3 of the glandular epithelial cells were
used for scoring as previously described [6,18]. The scores
employed were; negative, no positive cells; + < 10% posi-
tive cells; ++ 10–50% positive cells; +++ > 50% positive
cells. The mean scores between groups were analyzed by
the Student's t-Test
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